癌症免疫治疗学会关于免疫疗法治疗多发性骨髓瘤的共识声明。
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.
机构信息
Division of Hematology-Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Patient Empowerment Network, San Jose, California, USA.
出版信息
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000734.
Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome inhibitors and monoclonal antibodies. In recent years, immunotherapy for the treatment of MM has advanced rapidly, with the approval of new targeted agents and monoclonal antibodies directed against myeloma cell-surface antigens, as well as maturing data from late stage trials of chimeric antigen receptor CAR T cells. Therapies that engage the immune system to treat myeloma offer significant clinical benefits with durable responses and manageable toxicity profiles, however, the appropriate use of these immunotherapy agents can present unique challenges for practicing physicians. Therefore, the Society for Immunotherapy of Cancer convened an expert panel, which met to consider the current role of approved and emerging immunotherapy agents in MM and provide guidance to the oncology community by developing consensus recommendations. As immunotherapy evolves as a therapeutic option for the treatment of MM, these guidelines will be updated.
在过去的二十年中，随着新型疗法（包括免疫调节剂[IMiD]、蛋白酶体抑制剂和单克隆抗体）的出现，多发性骨髓瘤（MM）的治疗效果有了显著改善。近年来，MM 的免疫治疗迅速发展，新的靶向药物和针对骨髓瘤细胞表面抗原的单克隆抗体获得批准，以及嵌合抗原受体 CAR T 细胞的后期试验的成熟数据。利用免疫系统治疗骨髓瘤的疗法具有显著的临床获益，持久的反应和可管理的毒性特征，然而，这些免疫治疗药物的合理应用可能会给执业医师带来独特的挑战。因此，癌症免疫治疗学会召集了一个专家小组，该小组开会讨论了已批准和新兴的免疫治疗药物在 MM 中的当前作用，并通过制定共识建议为肿瘤学界提供指导。随着免疫疗法作为 MM 治疗的一种治疗选择不断发展，这些指南将不断更新。
Zotero 插件